|
ES2378473T3
(es)
*
|
2005-12-21 |
2012-04-12 |
Abbott Laboratories |
Compuestos antivirales
|
|
EP1971611B1
(en)
|
2005-12-21 |
2012-10-10 |
Abbott Laboratories |
Anti-viral compounds
|
|
CN101558067B
(zh)
*
|
2006-08-23 |
2014-05-28 |
库多斯药物有限公司 |
作为mtor抑制剂的2-甲基吗啉吡啶并、吡唑并和嘧啶并-嘧啶衍生物
|
|
HUE033894T2
(en)
*
|
2006-08-23 |
2018-01-29 |
Kudos Pharm Ltd |
2-Methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as MTOR inhibitors
|
|
US8236950B2
(en)
|
2006-12-20 |
2012-08-07 |
Abbott Laboratories |
Anti-viral compounds
|
|
US8138191B2
(en)
|
2007-01-11 |
2012-03-20 |
Critical Outcome Technologies Inc. |
Inhibitor compounds and cancer treatment methods
|
|
WO2009039140A1
(en)
*
|
2007-09-17 |
2009-03-26 |
Smithkline Beecham Corporation |
Pyridopyrimidine derivatives as pi3 kinase inhibitors
|
|
MX2010004074A
(es)
*
|
2007-10-15 |
2010-07-02 |
Astrazeneca Ab |
Combinacion 059.
|
|
US8466151B2
(en)
|
2007-12-26 |
2013-06-18 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
|
EP2262504A1
(en)
*
|
2008-02-21 |
2010-12-22 |
AstraZeneca AB |
Combination therapy 238
|
|
UY31917A
(es)
*
|
2008-06-20 |
2010-01-29 |
Astrazeneca Ab |
Compuestos de pirido-pirimidina inhibidores de mtor, composiciones farmaceuticas que los comprenden, procesos para su preparación y su uso como medicamento.
|
|
CA2729045A1
(en)
*
|
2008-07-31 |
2010-02-04 |
Philippe Bergeron |
Pyrimidine compounds, compositions and methods of use
|
|
JP2012506898A
(ja)
*
|
2008-10-31 |
2012-03-22 |
ノバルティス アーゲー |
ホスファチジルイノシトール−３−キナーゼ（ＰＩ３Ｋ）阻害剤とｍＴＯＲ阻害剤との併用剤
|
|
US8242260B2
(en)
|
2009-08-28 |
2012-08-14 |
Novartis Ag |
Compounds and compositions as protein kinase inhibitors
|
|
AU2010322114B2
(en)
|
2009-11-18 |
2014-07-31 |
Novartis Ag |
Methods and compositions for treating solid tumors and other malignancies
|
|
WO2011067356A2
(en)
|
2009-12-03 |
2011-06-09 |
Novartis Ag |
Polymorphs of a mek inhibitor
|
|
WO2011067348A2
(en)
|
2009-12-03 |
2011-06-09 |
Novartis Ag |
Mek inhibitor salts and solvates thereof
|
|
EP2992878A1
(en)
|
2010-02-03 |
2016-03-09 |
Signal Pharmaceuticals, LLC |
Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
|
|
EP2539337A1
(en)
*
|
2010-02-22 |
2013-01-02 |
F. Hoffmann-La Roche AG |
Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
|
|
WO2011120911A1
(en)
|
2010-03-30 |
2011-10-06 |
Novartis Ag |
Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling
|
|
EP3235818A3
(en)
|
2010-04-01 |
2018-03-14 |
Critical Outcome Technologies, Inc. |
Compounds for the treatment of hiv
|
|
ES2689177T3
(es)
|
2010-04-13 |
2018-11-08 |
Novartis Ag |
Combinación que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (CDK4/6) y un inhibidor de mTOR para tratar cáncer
|
|
KR20130048293A
(ko)
|
2010-06-25 |
2013-05-09 |
노파르티스 아게 |
단백질 키나제 억제제로서의 헤테로아릴 화합물 및 조성물
|
|
WO2012099581A1
(en)
|
2011-01-19 |
2012-07-26 |
Takeda Pharmaceutical Company Limited |
Dihydrofuropyrimidine compounds
|
|
AU2012290056B2
(en)
|
2011-08-03 |
2015-03-19 |
Signal Pharmaceuticals, Llc |
Identification of gene expression profile as a predictive biomarker for LKB1 status
|
|
CN102911172A
(zh)
*
|
2011-08-04 |
2013-02-06 |
上海恒瑞医药有限公司 |
杂芳基并嘧啶类衍生物、其制备方法和用途
|
|
CN103374021B
(zh)
*
|
2012-04-21 |
2015-10-28 |
通化济达医药有限公司 |
含有锌结合基的吡啶并嘧啶类HDAC和mTOR抑制剂
|
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
|
ES2821102T3
(es)
|
2012-11-29 |
2021-04-23 |
Merck Patent Gmbh |
Derivados de azaquinazolincarboxamida
|
|
CA2909579A1
(en)
|
2013-04-17 |
2014-10-23 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
|
|
EA030808B1
(ru)
|
2013-04-17 |
2018-09-28 |
СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
ПРИМЕНЕНИЕ 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1Н-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1Н)-ОНА В ЛЕЧЕНИИ МУЛЬТИФОРМНОЙ ГЛИОБЛАСТОМЫ
|
|
HK1221174A1
(zh)
|
2013-04-17 |
2017-05-26 |
西格诺药品有限公司 |
用於治疗癌症的包括tor激酶抑制剂和5-取代喹唑啉酮化合物的组合疗法
|
|
MX364101B
(es)
|
2013-04-17 |
2019-04-12 |
Signal Pharm Llc |
Terapia de combinación que comprende un compuesto de dihidropirazino-pirazina y un antagonista de receptor de andrógenos para tratar cáncer de próstata.
|
|
SG11201508527VA
(en)
|
2013-04-17 |
2015-11-27 |
Signal Pharm Llc |
Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
|
|
WO2014172432A1
(en)
|
2013-04-17 |
2014-10-23 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
|
|
HK1221150A1
(zh)
|
2013-04-17 |
2017-05-26 |
西格诺药品有限公司 |
用二氢吡嗪并-吡嗪类对癌症的治疗
|
|
CA3143529A1
(en)
|
2013-05-29 |
2014-12-04 |
Signal Pharmaceuticals, Llc |
Pharmaceutical compositions 0f 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
|
|
WO2015160880A1
(en)
|
2014-04-16 |
2015-10-22 |
Signal Pharmaceuticals, Llc |
SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
|
|
NZ714742A
(en)
|
2014-04-16 |
2017-04-28 |
Signal Pharm Llc |
Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
|
|
TWI656121B
(zh)
*
|
2014-08-04 |
2019-04-11 |
德商拜耳製藥公司 |
２－（嗎啉－４－基）－１，７－萘啶
|
|
CN106008559B
(zh)
*
|
2015-03-25 |
2020-10-16 |
中国科学院上海药物研究所 |
取代吡啶并嘧啶类化合物的合成工艺
|
|
WO2018144791A1
(en)
*
|
2017-02-03 |
2018-08-09 |
Millennium Pharmaceuticals, Inc. |
Combination of vps34 inhibitors and mtor inhibitors
|
|
MY198676A
(en)
|
2017-06-22 |
2023-09-15 |
Celgene Corp |
Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
|
|
RU2771201C2
(ru)
*
|
2017-11-06 |
2022-04-28 |
Медшайн Дискавери Инк. |
ПИРИДОПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ, ВЫПОЛНЯЮЩИЕ ФУНКЦИЮ ДВОЙНЫХ ИНГИБИТОРОВ mTORC 1/2
|
|
WO2021133509A1
(en)
*
|
2019-12-27 |
2021-07-01 |
Angex Pharmaceutical, Inc. |
Heterocyclic compounds as mtor inhibitors
|
|
CA3167339A1
(en)
|
2020-01-13 |
2021-07-22 |
Verge Analytics, Inc. |
Substituted pyrazolo-pyrimidines and uses thereof
|
|
EP4161926A4
(en)
*
|
2020-06-03 |
2024-06-19 |
Yumanity Therapeutics, Inc. |
PYRIDOPYRIMIDINES AND THEIR METHODS OF USE
|
|
WO2022042630A1
(en)
*
|
2020-08-26 |
2022-03-03 |
InventisBio Co., Ltd. |
Heteroaryl compounds, preparation methods and uses thereof
|
|
CN117088898A
(zh)
*
|
2022-05-13 |
2023-11-21 |
中国药科大学 |
稠环嘧啶类化合物及其制备方法、药物组合物和应用
|
|
WO2024057013A1
(en)
*
|
2022-09-12 |
2024-03-21 |
Exscientia Ai Limited |
Nlrp3 modulators
|